Daily Bulletin

The Conversation

  • Written by The Conversation
imageFunding is one but it won't happen without the other two.Counting by Shutterstock

An estimated 36m people worldwide suffer from dementia. Alzheimer’s disease is the biggest cause, but the treatments available are inadequate only improving some of the symptoms. In the decade between 2002 and 2012 there were 244 drugs trialled in patients yet just one of these trials resulted in a drug being approved for treatment – a failure rate of 99.6%.

This sustained failure makes investing money in these expensive trials very risky, and has led to a number of pharmaceutical companies stopping or reducing research in these areas. Due to increased life expectancy, particularly in developing countries the number of cases of dementia is predicted to triple by 2050. Dementia is already the leading cause of death of women in the UK and the fifth highest cause of death in men.

The lack of treatments, devastating impact and economic burden that dementia places on society makes developing effective treatments one of our most urgent unmet clinical needs. There are often sensationalised reports in the media claiming that we have discovered a cure for dementia, but why have these discoveries not led to an actual benefit for patients?

Finding it long before the signs

We first notice Alzheimer’s when patients begin to develop memory impairments and other cognitive problems, however the disease processes is thought to begin decades before. Because Alzheimer’s disease occurs over such a long period of time, it makes studying the disease both difficult and expensive.

Despite these difficulties significant progress has been made in identifying genetic and environmental factors that increase the risk of developing Alzheimer’s disease. This in turn has generated targets for new drugs, such as factors in the immune system or proteins in the brain, but patience is needed as the process of developing new drugs is a long and costly one.

imageBy the time we see it, the damage is already done.Middle age by Shutterstock

Unfortunately by the time clinical symptoms of Alzheimer’s disease happen, the patient has already suffered significant brain damage. So an explanation for the failure of so many trials is that we are treating too late in the disease, and that these drugs may actually have been successful if given earlier on. This is a problem as currently the only way to confirm the diagnosis of Alzheimer’s disease is by looking at the brain after death, which means identifying patients early for drug trials is very challenging.

It has been shown that a significant number of patients enrolled on drug trials did not actually have Alzheimer’s disease. This is a huge issue as those patients would never have responded to the treatments, and it makes it much harder to detect any beneficial effects of the drug. New research is allowing more certain diagnosis of Alzheimer’s disease, however early and reliable diagnosis is still a long way off.

Moving animal research to humans

Animals such as mice and rats are used to model Alzheimer’s disease and to test new drugs on. Many drugs work fantastically well in these animal models, but are ineffective in humans. This is due to differences between the models and the human disease, and representing Alzheimer’s disease in the lab is actually very challenging. This is partly because we do not understand the disease process, but it also comes down to time. Alzheimer’s disease develops over decades, yet the average lifespan of a mouse is a couple of years. This makes it impossible to represent one of the most important aspects of the disease – ageing.

A focus on funding

The economic cost of Alzheimer’s disease and other causes of dementia is higher than that of cancer, in the UK it is thought to cost cost the UK economy about £26 billion a year, around £10 billion more than cancer. However ten times less money is spent researching dementia than cancer.

The prime minister committed to doubling funding for dementia research by 2025. Although this still leaves dementia significantly behind, increasing funding – and therefore the number of scientists working in this area – will help to improve our understanding of dementia and will enable earlier diagnosis and better modelling of Alzheimer’s disease in the lab. A new drug called Aducanumab is showing promising signs in early human trials. Lets hope for more.

James Fuller receives funding from the Medical Research Council and Lundbeck A/S

Authors: The Conversation

Read more http://theconversation.com/three-things-we-have-to-crack-before-we-can-find-any-cures-for-alzheimers-42963

Writers Wanted

Israel-Palestinian violence: why East Jerusalem has become a flashpoint in a decades-old conflict

arrow_forward

How much can I spend on my home renovation? A personal finance expert explains

arrow_forward

4 Top Reasons to Install Range Hoods

arrow_forward

The Conversation
INTERWEBS DIGITAL AGENCY

Politics

Prime Minister interview with Karl Stefanovic and Allison Langdon

Karl Stefanovic: PM, good morning to you. Do you have blood on your hands?   PRIME MINISTER: No, it's obviously absurd. What we're doing here is we've got a temporary pause in place because we'v...

Karl Stefanovic and Allison Langdon - avatar Karl Stefanovic and Allison Langdon

Prime Minister Scott Morrison delivered Keynote Address at AFR Business Summit

Well, thank you all for the opportunity to come and be with you here today. Can I also acknowledge the Gadigal people, the Eora Nation, the elders past and present and future. Can I also acknowled...

Scott Morrison - avatar Scott Morrison

Morrison Government commits record $9B to social security safety net

The Morrison Government is enhancing our social security safety net by increasing support for unemployed Australians while strengthening their obligations to search for work.   From March the ...

Scott Morrison - avatar Scott Morrison

Business News

The Age Of Advertising: The Importance of Online Business Advertisements

The language of advertising had long grown since its modern beginning in the 15th century when printing was all the jazz. Nowadays, it continues to flourish and adapt as new mediums are created, a...

NewsCo - avatar NewsCo

What is Hampering Your Good Sleep? 7 Things to Check

A good sleep is the pillar of a healthy body and a strong mind. Countless studies have proven how a good night’s sleep goes hand in hand with good health and a productive day ahead. Sleep has an i...

NewsCo - avatar NewsCo

Perks of Acquiring an Established Business

There is a growing trend of buying well-established businesses in Australia. It seems like budding entrepreneurs are finally understanding the perks of buying an established firm as opposed to start...

NewsCo - avatar NewsCo